Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death

Impaired tumor suppressor functions, such as deficient p53, are characteristic for glioblastoma multiforme (GBM) and can cause resistance to DNA-damaging agents like cisplatin. We have recently shown that the INhibitor of Growth 1 (ING1) tumor suppressor is down-regulated in malignant gliomas and that the decrease of ING1 expression correlates with histological grade of malignancy, suggesting a role for ING1 in the pathogenesis and progression of malignant gliomas. Based on this background, the purpose of our current study was to examine the potential impact of ING1 protein levels on DNA-damage response in GBM. Using LN229 GBM cells, which express ING1 proteins and harbor mutant TP53, we are the first to show that DNA damage by cisplatin or ionizing radiation differentially induced the two major ING1 splicing isoforms. The p47ING1a isoform, that promotes deacetylation of histones, thus formation of heterochromatic regions of DNA, which are less susceptible to DNA damage, was preferentially induced by >50-fold. This might represent a response to protect DNA from damage. Also, ING1 knockdown by siRNA accelerated transit of cells through G1 phase, consistent with ING1 serving a tumor suppressor function, and caused cells to enter apoptosis more rapidly in response to cisplatin. Our results indicate that malignant gliomas may down-regulate ING1 to allow more efficient tumor growth and progression. Also, ING1 down-regulation may sensitize GBM cells with deficient p53 to treatment with cisplatin.

[1]  H. Bernstein,et al.  DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. , 2002, Mutation research.

[2]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[3]  Gang Li,et al.  p33(ING1) enhances UVB-induced apoptosis in melanoma cells. , 2002, Experimental cell research.

[4]  T. Furukawa,et al.  Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. , 1999, Cancer research.

[5]  A. Merlo,et al.  Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines. , 1999, Brain pathology.

[6]  K. Riabowol,et al.  Grow-ING, Age-ING and Die-ING: ING proteins link cancer, senescence and apoptosis. , 2006, Experimental cell research.

[7]  I. Garkavtsev,et al.  The candidate tumour suppressor p33ING1cooperates with p53 in cell growth control , 1998, Nature.

[8]  K. Riabowol,et al.  Different HATS of the ING1 gene family. , 2002, Trends in cell biology.

[9]  H. Ngan,et al.  Epigenetic and genetic alterations of p33ING1b in ovarian cancer. , 2005, Carcinogenesis.

[10]  Jun-min Zhou,et al.  The tumor suppressor p33ING1b enhances taxol-induced apoptosis by p53-dependent pathway in human osteosarcoma U2OS cells , 2005, Cancer biology & therapy.

[11]  T. McMillan,et al.  Application of a bromodeoxyuridine-Hoechst/ethidium bromide technique for the analysis of radiation-induced cell cycle delays in asynchronous cell populations. , 1996, International journal of radiation biology.

[12]  Song Tan,et al.  ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. , 2006, Molecular cell.

[13]  C. Rhee,et al.  Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin. , 2006, International journal of oncology.

[14]  Tao Liu,et al.  Histone deacetylase inhibitors: multifunctional anticancer agents. , 2006, Cancer treatment reviews.

[15]  K. Riabowol,et al.  Function of the ING family of PHD proteins in cancer. , 2005, The international journal of biochemistry & cell biology.

[16]  A. Abbruzzese,et al.  Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia , 2005, Cancer biology & therapy.

[17]  D. Reinberg,et al.  ING 1 Candidate Tumor Suppressor p 33 Complex in Growth Regulation by the Role of the Sin 3-Histone Deacetylase , 2001 .

[18]  Anjanabha Saha,et al.  ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression , 2006, Nature.

[19]  K. Riabowol,et al.  Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  V. Verkhusha,et al.  Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2 , 2006, Nature.

[21]  F. Boisvert,et al.  UV-induced binding of ING1 to PCNA regulates the induction of apoptosis. , 2001, Journal of cell science.

[22]  C. Tsang,et al.  Nutrient regulates Tor1 nuclear localization and association with rDNA promoter , 2006, Nature.

[23]  G. Barger,et al.  In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas , 2006, Clinical Cancer Research.

[24]  K. Riabowol,et al.  Expression of p33ING1 mRNA and chemosensitivity in brain tumor cells. , 2003, Anticancer research.

[25]  K. Riabowol,et al.  A panel of CAb antibodies recognize endogenous and ectopically expressed ING1 protein. , 2000, Hybridoma.

[26]  D. Patel,et al.  Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF , 2006, Nature.

[27]  K. Riabowol,et al.  HSP70 Induction by ING Proteins Sensitizes Cells to Tumor Necrosis Factor Alpha Receptor-Mediated Apoptosis , 2006, Molecular and Cellular Biology.

[28]  Rapid purification of protein complexes from mammalian cells. , 2000, Nucleic acids research.

[29]  K. Riabowol,et al.  ING1 isoforms differentially affect apoptosis in a cell age-dependent manner. , 2002, Cancer research.

[30]  I. Garkavtsev,et al.  Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation , 1996, Nature Genetics.

[31]  J. Cairncross,et al.  Inactivation of p53 Sensitizes Astrocytic Glioma Cells to BCNU and Temozolomide, but not Cisplatin , 2005, Journal of Neuro-Oncology.

[32]  D. Demetrick,et al.  Cellular localization and chromosome mapping of a novel candidate tumor suppressor gene (ING1). , 1997, Cytogenetics and cell genetics.

[33]  I. Garkavtsev,et al.  A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. , 1997, Cancer research.

[34]  A. Nakagawara,et al.  Decreased expression of the candidate tumor suppressor gene ING1 is associated with poor prognosis in advanced neuroblastomas. , 2004, Oncology reports.

[35]  A. von Deimling,et al.  No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma , 2004, International journal of cancer.

[36]  Or Gozani,et al.  The Yng1p Plant Homeodomain Finger Is a Methyl-Histone Binding Module That Recognizes Lysine 4-Methylated Histone H3 , 2006, Molecular and Cellular Biology.

[37]  Stephen N. Jones,et al.  Deletion of p37Ing1 in mice reveals a p53-independent role for Ing1 in the suppression of cell proliferation, apoptosis, and tumorigenesis. , 2007, Cancer research.

[38]  Gang Li,et al.  The tumor suppressor candidate p33(ING1) mediates repair of UV-damaged DNA. , 2001, Cancer research.

[39]  D. Ayer,et al.  The Polybasic Region That Follows the Plant Homeodomain Zinc Finger 1 of Pf1 Is Necessary and Sufficient for Specific Phosphoinositide Binding* , 2006, Journal of Biological Chemistry.

[40]  F. Boisvert,et al.  Human ING1 Proteins Differentially Regulate Histone Acetylation* , 2002, The Journal of Biological Chemistry.

[41]  R. Schlapbach,et al.  Differential activity of bcl-2 and ICE enzyme family protease inhibitors on Fas and puromycin-induced apoptosis of glioma cells. , 1997, Biochimica et biophysica acta.

[42]  F. Boisvert,et al.  UV induces nucleolar translocation of ING1 through two distinct nucleolar targeting sequences. , 2001, Nucleic acids research.

[43]  H. G. Einsiedel,et al.  Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology. , 2001, Clinical chemistry.

[44]  R. King,et al.  Cell biology: Nondisjunction, aneuploidy and tetraploidy (Reply) , 2006, Nature.